See more : Luolai Lifestyle Technology Co., Ltd. (002293.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of YS Biopharma Co., Ltd. (YS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of YS Biopharma Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Nisshin Seifun Group Inc. (NSFMF) Income Statement Analysis – Financial Results
- Tourism Holdings Limited (THL.AX) Income Statement Analysis – Financial Results
- Progress Software Corporation (PRGS) Income Statement Analysis – Financial Results
- Robinson plc (RBN.L) Income Statement Analysis – Financial Results
- Chiho Environmental Group Limited (0976.HK) Income Statement Analysis – Financial Results
YS Biopharma Co., Ltd. (YS)
About YS Biopharma Co., Ltd.
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 687.20M | 502.95M | 257.02M |
| Cost of Revenue | 153.36M | 117.07M | 59.66M |
| Gross Profit | 533.84M | 385.88M | 197.36M |
| Gross Profit Ratio | 77.68% | 76.72% | 76.79% |
| Research & Development | 318.70M | 211.22M | 94.39M |
| General & Administrative | 81.76M | 107.05M | 138.89M |
| Selling & Marketing | 251.56M | 165.72M | 69.44M |
| SG&A | 333.32M | 272.77M | 208.33M |
| Other Expenses | -199.45K | -2.41M | -22.36M |
| Operating Expenses | 647.15M | 481.82M | 319.68M |
| Cost & Expenses | 800.51M | 598.89M | 379.33M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 30.86M | 2.72M | 29.69M |
| Depreciation & Amortization | 36.69M | 31.15M | 27.91M |
| EBITDA | -76.82M | -67.20M | -116.78M |
| EBITDA Ratio | -11.18% | -13.36% | -45.44% |
| Operating Income | -139.38M | -118.96M | -125.85M |
| Operating Income Ratio | -20.28% | -23.65% | -48.96% |
| Total Other Income/Expenses | -4.96M | 17.89M | -48.52M |
| Income Before Tax | -144.35M | -101.07M | -174.37M |
| Income Before Tax Ratio | -21.00% | -20.09% | -67.84% |
| Income Tax Expense | 1.13M | 4.94M | 17.45M |
| Net Income | -145.48M | -106.00M | -191.83M |
| Net Income Ratio | -21.17% | -21.08% | -74.64% |
| EPS | -1.56 | -1.15 | -2.08 |
| EPS Diluted | -1.56 | -1.15 | -2.08 |
| Weighted Avg Shares Out | 93.06M | 92.17M | 92.17M |
| Weighted Avg Shares Out (Dil) | 93.06M | 92.17M | 92.17M |
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting
Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.
YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance
YS Biopharma Announces Appointment of New Directors
YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.
YS Biopharma Announces US$40 Million Private Placement Financing
Shareholders of YS Biopharma Announce an Extraordinary General Meeting
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
Source: https://incomestatements.info
Category: Stock Reports